Auron to Present New Preclinical Data for AUTX-703 at 2024 ASH Meeting
November 05, 2024 09:00 ET
|
Auron Therapeutics Inc.
NEWTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Auron Therapeutics, a biotechnology company focused on developing next-generation targeted therapies by identifying and inhibiting the oncogenic cell...
Auron Presents New Preclinical Data for Lead Program AUTX-703 Across Multiple Cancer Types
October 24, 2024 07:00 ET
|
Auron Therapeutics Inc.
Treatment with AUTX-703 resulted in notable cell differentiation and tumor growth inhibition in various primary cancer models AUTX-703 IND submission on track for late 2024 NEWTON, Mass. , Oct. 24,...
Auron Announces Poster Presentation at 2024 PCF Annual Scientific Retreat
October 11, 2024 08:00 ET
|
Auron Therapeutics Inc.
NEWTON, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Auron Therapeutics, a biotechnology company focused on developing next-generation targeted therapies by identifying and inhibiting the oncogenic cell...
Auron to Present AUTX-703 Preclinical Data 2024 ENA Symposium
October 09, 2024 08:00 ET
|
Auron Therapeutics Inc.
NEWTON, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Auron Therapeutics, a biotechnology company focused on developing next-generation targeted therapies by identifying and inhibiting the oncogenic cell...
Auron Presents Preclinical Data at American Chemical Society Annual Meeting
August 19, 2024 08:00 ET
|
Auron Therapeutics Inc.
NEWTON, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Auron Therapeutics, a biotechnology company focused on developing next-generation targeted therapies by identifying and inhibiting the oncogenic cell...
Auron Announces Oral Presentation on Preclinical Data from Proprietary AURIGIN™ Platform at the AI in Biomedicine Keystone Symposia
May 01, 2024 08:00 ET
|
Auron Therapeutics Inc.
NEWTON, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Auron Therapeutics, a biotechnology company focused on developing next-generation targeted therapies by identifying and inhibiting the oncogenic cell...
Auron Unveils Preclinical Data Supporting its Lead Program and Ability of its AURIGIN™ Platform to Generate Targeted Cancer Therapies at AACR Annual Meeting
April 09, 2024 16:30 ET
|
Auron Therapeutics Inc.
Preclinical data from lead program addressing AURIGIN-identified KAT2A/B target showed significant cell state shift and tumor growth inhibition across multiple primary cancer models AURIGIN overview...
Auron Announces Poster Presentations at 2024 AACR Annual Meeting
March 06, 2024 08:00 ET
|
Auron Therapeutics Inc.
NEWTON, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Auron Therapeutics, a biotechnology company focused on developing next-generation targeted therapies by identifying and inhibiting the oncogenic...
Auron Selects First Development Candidate for its Portfolio of Next-Generation Targeted Cancer Treatments from its Novel AURIGIN™ Platform
February 08, 2024 08:00 ET
|
Auron Therapeutics Inc.
AUTX-703 has demonstrated potent growth inhibition in preclinical models of solid tumors and a hematological malignancy An overview of the Company’s AURIGIN platform to be presented at the American...
Auron Strengthens Board of Directors and Leadership Team with Industry Veterans, Victoria Richon, Ph.D. and Christopher Guiffre, J.D., MBA
August 10, 2023 11:08 ET
|
Auron Therapeutics Inc.
NEWTON, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Auron Therapeutics, a platform-based, product-driven biotechnology company focused on discovering and developing novel cancer therapies using its...